You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
健帆生物(300529.SZ):2024年度淨利潤預增83%-97%
格隆匯 01-21 21:48

格隆匯1月21日丨健帆生物(300529.SZ)公佈2024年度業績預增公吿,2024年營業收入25.95億元~27.87億元,比上年同期增長35%~45%;歸屬於上市公司股東的淨利潤盈利8億元~8.6億元,比上年同期增長83%~97%;扣除非經常性損益後的淨利潤盈利7.45億元~8.05億元,比上年同期增長82%~97%。

報吿期內,公司外部政策環境得到一定改善。公司持續發揮在血液灌流領域的科技及市場領先優勢,在腎病、肝病、危急重症等領域業務發展態勢良好,實現公司營業收入同比增長。公司以增效降本原則開展各類經營活動,期間費用率同比下降,因此歸屬於上市公司股東的淨利潤同比實現大幅增長。

2024年非經常性損益對淨利潤的影響金額約為5,480萬元,主要系政府補助和購買理財產品的收益。2023年非經常性損益金額為2,744.92萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account